Clinical Trial Update: Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating maintenance fedratinib to prevent post-transplant relapse in myeloproliferative neoplasms has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasm

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myeloproliferative Neoplasm | Phase 1 | Status: TERMINATED